← Leaderboards
Dan Gabriel Duda
Duke University
$6,457,636
Attributed
$10,777,345
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,777,345 · 9
By mechanism
R01$8,647,513 · 5
P01$1,250,366 · 1
R21$412,147 · 1
R41$299,999 · 1
R03$167,320 · 1
Top collaborators
- Anand T.N. Kumar6 shared
- Hesham M Amin5 shared
- Ahmed Kaseb5 shared
- Lance L Munn4 shared
- Gaorav P. Gupta2 shared
- Michael Briggs1 shared
- Dana Casey1 shared
- Soldano Ferrone1 shared
Most similar at Duke University
Same institution · by research overlap
- Matthew J Ellis$25,349,408
- Kafui Dzirasa$13,952,017
- Linda B. Mc Gown$2,489,698
- Lawrence S. Barak$6,045,982
- Anil Potti$664,164
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorBlood VesselsIn VivoResponseCellsTissuesMalignant NeoplasmsCancer CellPathway InteractionsCombined Modality TherapyDesignGrowthPharmaceutical PreparationsClinically RelevantImmuneIn VitroOperative Surgical ProceduresApoptosisTumor GrowthImplantNovel StrategiesResistanceImageExcision
Grant awards (32)
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients$461,706
R01 · FY2025 · CA
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy$457,001
R01 · FY2025 · CA
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients$590,031
R01 · FY2024 · CA
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy$436,422
R01 · FY2024 · CA
Vascularized tumor explants for drug testing$359,175
R01 · FY2024 · CA
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients$608,666
R01 · FY2023 · CA
Vascularized tumor explants for drug testing$370,516
R01 · FY2023 · CA
Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer$355,463
R01 · FY2023 · CA
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy$240,698
R01 · FY2023 · CA
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy$205,000
R01 · FY2023 · CA
Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer$1
R01 · FY2023 · CA
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients$608,661
R01 · FY2022 · CA
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy$443,281
R01 · FY2022 · CA
Vascularized tumor explants for drug testing$370,516
R01 · FY2022 · CA
Radiation and CSPG4-specifc CAR T cell based combinatorial therapy for the in vivo treatment of TNBC$83,660
R03 · FY2022 · CA · contact PI
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients$711,171
R01 · FY2021 · CA
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy$463,813
R01 · FY2021 · CA
Vascularized tumor explants for drug testing$378,078
R01 · FY2021 · CA
Radiation and CSPG4-specifc CAR T cell based combinatorial therapy for the in vivo treatment of TNBC$83,660
R03 · FY2021 · CA
Development, Characterization & Commercialization of a Viably Frozen, Patient-Inclusive Hepatocellular Carcinoma Tumor Bank$299,999
R41 · FY2017 · CA
Overcoming Evasion from Sorafenib in HCC$254,705
P01 · FY2016 · CA · contact PI
Role of SDF1a pathway in prostate cancer relapse and metastasis post-radiotherapy$324,945
R01 · FY2015 · CA · contact PI
Overcoming Evasion from Sorafenib in HCC$254,705
P01 · FY2015 · CA · contact PI
Role of SDF1a pathway in prostate cancer relapse and metastasis post-radiotherapy$315,197
R01 · FY2014 · CA · contact PI
Overcoming Evasion from Sorafenib in HCC$246,215
P01 · FY2014 · CA · contact PI
Role of SDF1a pathway in prostate cancer relapse and metastasis post-radiotherapy$305,448
R01 · FY2013 · CA · contact PI
Overcoming Evasion from Sorafenib in HCC$239,426
P01 · FY2013 · CA · contact PI
Role of SDF1a pathway in prostate cancer relapse and metastasis post-radiotherapy$324,874
R01 · FY2012 · CA · contact PI
Overcoming Evasion from Sorafenib in HCC$255,315
P01 · FY2012 · CA · contact PI
Role of SDF1a pathway in prostate cancer relapse and metastasis post-radiotherapy$316,850
R01 · FY2011 · CA · contact PI
Visualizing Immune Responses in vivo: a systems biology approach$186,603
R21 · FY2010 · CA · contact PI
Visualizing Immune Responses in vivo: a systems biology approach$225,544
R21 · FY2009 · CA · contact PI